182 related articles for article (PubMed ID: 26485399)
1. Use of In Vitro and Predictive In Silico Models to Study the Inhibition of Cytochrome P4503A by Stilbenes.
Basheer L; Schultz K; Fichman M; Kerem Z
PLoS One; 2015; 10(10):e0141061. PubMed ID: 26485399
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cytochrome P450 3A by acetoxylated analogues of resveratrol in in vitro and in silico models.
Basheer L; Schultz K; Kerem Z
Sci Rep; 2016 Aug; 6():31557. PubMed ID: 27530542
[TBL] [Abstract][Full Text] [Related]
3. In silico and in vitro inhibition of cytochrome P450 3A by synthetic stilbenoids.
Basheer L; Schultz K; Guttman Y; Kerem Z
Food Chem; 2017 Dec; 237():895-903. PubMed ID: 28764083
[TBL] [Abstract][Full Text] [Related]
4. Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects.
Li Y; Ning J; Wang Y; Wang C; Sun C; Huo X; Yu Z; Feng L; Zhang B; Tian X; Ma X
Toxicol Lett; 2018 Sep; 294():27-36. PubMed ID: 29753067
[TBL] [Abstract][Full Text] [Related]
5. beta-caryophyllene oxide and trans-nerolidol affect enzyme activity of CYP3A4 - in vitro and in silico studies.
Špičáková A; Bazgier V; Skálová L; Otyepka M; Anzenbacher P
Physiol Res; 2019 Nov; 68(Suppl 1):S51-S58. PubMed ID: 31755290
[TBL] [Abstract][Full Text] [Related]
6. Influence of lipophilicity on the interactions of hydroxy stilbenes with cytochrome P450 3A4.
Regev-Shoshani G; Shoseyov O; Kerem Z
Biochem Biophys Res Commun; 2004 Oct; 323(2):668-73. PubMed ID: 15369802
[TBL] [Abstract][Full Text] [Related]
7. Single-Walled Carbon Nanotubes Inhibit the Cytochrome P450 Enzyme, CYP3A4.
El-Sayed R; Bhattacharya K; Gu Z; Yang Z; Weber JK; Li H; Leifer K; Zhao Y; Toprak MS; Zhou R; Fadeel B
Sci Rep; 2016 Feb; 6():21316. PubMed ID: 26899743
[TBL] [Abstract][Full Text] [Related]
8. The effect of resveratrol on pharmacokinetics of aripiprazole in vivo and in vitro.
Zhan YY; Liang BQ; Li XY; Gu EM; Dai DP; Cai JP; Hu GX
Xenobiotica; 2016; 46(5):439-44. PubMed ID: 26391142
[TBL] [Abstract][Full Text] [Related]
9. Computational Investigation of Ligand Binding to the Peripheral Site in CYP3A4: Conformational Dynamics and Inhibitor Discovery.
Du H; Li J; Cai Y; Zhang H; Liu G; Tang Y; Li W
J Chem Inf Model; 2017 Mar; 57(3):616-626. PubMed ID: 28221037
[TBL] [Abstract][Full Text] [Related]
10. Screening and verification of CYP3A4 inhibitors from Bushen-Yizhi formula to enhance the bioavailability of osthole in rat plasma.
Liu JM; Chen JM; Lin MJ; Wu FC; Ma CR; Zuo X; Yu WQ; Huang MJ; Fang JS; Li WR; Wang Q; Liang Y
J Ethnopharmacol; 2022 Jan; 282():114643. PubMed ID: 34534597
[TBL] [Abstract][Full Text] [Related]
11. Differential Reversible and Irreversible Interactions between Benzbromarone and Human Cytochrome P450s 3A4 and 3A5.
Tang LWT; Verma RK; Yong RP; Li X; Wang L; Lin Q; Fan H; Chan ECY
Mol Pharmacol; 2021 Sep; 100(3):224-236. PubMed ID: 34210765
[TBL] [Abstract][Full Text] [Related]
12. Curculigo orchioides (Xian Mao) modifies the activity and protein expression of CYP3A in normal and Kidney-Yang Deficiency model rats.
Wang CM; Xu SY; Lai S; Geng D; Huang JM; Huo XY
J Ethnopharmacol; 2012 Oct; 144(1):33-8. PubMed ID: 22974543
[TBL] [Abstract][Full Text] [Related]
13. Role of CYP3A in regulating hepatic clearance and hepatotoxicity of triptolide in rat liver microsomes and sandwich-cultured hepatocytes.
Shen G; Zhuang X; Xiao W; Kong L; Tan Y; Li H
Food Chem Toxicol; 2014 Sep; 71():90-6. PubMed ID: 24910460
[TBL] [Abstract][Full Text] [Related]
14. Modeling chemical interaction profiles: II. Molecular docking, spectral data-activity relationship, and structure-activity relationship models for potent and weak inhibitors of cytochrome P450 CYP3A4 isozyme.
Tie Y; McPhail B; Hong H; Pearce BA; Schnackenberg LK; Ge W; Buzatu DA; Wilkes JG; Fuscoe JC; Tong W; Fowler BA; Beger RD; Demchuk E
Molecules; 2012 Mar; 17(3):3407-60. PubMed ID: 22421793
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib N-Oxide Is an Inhibitor of Human Hepatic CYP3A4.
Ghassabian S; Gillani TB; Rawling T; Crettol S; Nair PC; Murray M
AAPS J; 2019 Jan; 21(2):15. PubMed ID: 30627802
[TBL] [Abstract][Full Text] [Related]
16. Interactions of casticin, ipriflavone, and resveratrol with serum albumin and their inhibitory effects on CYP2C9 and CYP3A4 enzymes.
Mohos V; Bencsik T; Boda G; Fliszár-Nyúl E; Lemli B; Kunsági-Máté S; Poór M
Biomed Pharmacother; 2018 Nov; 107():777-784. PubMed ID: 30142539
[TBL] [Abstract][Full Text] [Related]
17. Screening for CYP3A4 inhibition and induction coupled to parallel artificial membrane permeability assay (PAMPA) for prediction of botanical-drug interactions: The case of açaí and maca.
Zhang Y; Rants'o TA; Jung D; Lopez E; Abbott K; Pondugula SR; McLendon L; Qian J; Hansen RA; Calderón AI
Phytomedicine; 2019 Jun; 59():152915. PubMed ID: 30981185
[TBL] [Abstract][Full Text] [Related]
18. Co-treatment with indole-3-carbinol and resveratrol modify porcine CYP1A and CYP3A activities and expression.
Zamaratskaia G; Thøgersen R; Čandek-Potokar M; Rasmussen MK
Xenobiotica; 2018 Mar; 48(3):232-240. PubMed ID: 28316274
[TBL] [Abstract][Full Text] [Related]
19. Rapid screening the potential mechanism-based inhibitors of CYP3A4 from Tripterygium wilfordi based on computer approaches combined with in vitro bioassay.
Wang L; Hai Y; An L; Chen J; Liang R; He X
Bioorg Med Chem; 2017 May; 25(10):2689-2700. PubMed ID: 28372934
[TBL] [Abstract][Full Text] [Related]
20. In vitro metabolism of carbofuran by human, mouse, and rat cytochrome P450 and interactions with chlorpyrifos, testosterone, and estradiol.
Usmani KA; Hodgson E; Rose RL
Chem Biol Interact; 2004 Dec; 150(3):221-32. PubMed ID: 15560889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
